Joseph Frattaroli - Mar 7, 2022 Form 4 Insider Report for Inhibikase Therapeutics, Inc. (IKT)

Role: Chief Financial Officer
Signature: /s/ Joseph Frattaroli
Stock symbol: IKT
Transactions as of: Mar 7, 2022
Transactions value $: $0
Form type: 4
Date filed: 3/21/2022, 04:05 PM
Next filing: May 23, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	IKT	Common Stock						44.1K	Mar 7, 2022	By Flagship Consulting, Inc.

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IKT	Stock Option (right to buy)	Award	$0	+62.5K		$0.00	62.5K	Mar 7, 2022	Common Stock	62.5K	$1.07	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	One-third of the options will vest and become exercisable on 3/7/2023, and the remaining portion will vest and become exercisable in 24 equal monthly installments commencing on the first day of April 2023, subject to continued employment through each such vesting date.
F2	The original Form 4, filed on March 9, 2022, is being amended by this Form 4 amendment to correct an error that misreported that the 24 equal monthly installments mentioned in footnote 1 would begin on the first day of April 2024, rather than the first day of April 2023 as intended.